OraSure Technologies, Inc. (OSUR) CFO Ronald H. Spair Sells 72,564 Shares
OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Ronald H. Spair sold 72,564 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $15.00, for a total transaction of $1,088,460.00. Following the completion of the sale, the chief financial officer now owns 175,130 shares of the company’s stock, valued at $2,626,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
OraSure Technologies, Inc. (NASDAQ:OSUR) traded up 1.08% during trading on Tuesday, hitting $15.00. 1,304,913 shares of the stock traded hands. The firm has a 50-day moving average price of $12.61 and a 200 day moving average price of $10.01. OraSure Technologies, Inc. has a 12 month low of $5.57 and a 12 month high of $15.72. The firm has a market cap of $853.94 million, a PE ratio of 28.74 and a beta of 1.44.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.04. OraSure Technologies had a net margin of 15.38% and a return on equity of 11.64%. The firm had revenue of $32.55 million during the quarter, compared to analysts’ expectations of $31.19 million. During the same quarter in the prior year, the company earned $0.04 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. On average, equities analysts forecast that OraSure Technologies, Inc. will post $0.42 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/05/09/orasure-technologies-inc-osur-cfo-ronald-h-spair-sells-72564-shares.html.
A number of large investors have recently bought and sold shares of OSUR. Norges Bank purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $9,786,000. Dimensional Fund Advisors LP boosted its stake in OraSure Technologies by 29.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,494,674 shares of the medical instruments supplier’s stock worth $21,903,000 after buying an additional 569,993 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in OraSure Technologies by 107.4% in the first quarter. Bank of New York Mellon Corp now owns 816,172 shares of the medical instruments supplier’s stock worth $10,553,000 after buying an additional 422,645 shares during the last quarter. Sicart Associates LLC purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $3,240,000. Finally, Russell Investments Group Ltd. purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $2,076,000. 79.51% of the stock is owned by institutional investors.
Several analysts have commented on the stock. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Saturday. Jefferies Group LLC raised their price objective on shares of OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 4th. Canaccord Genuity set a $12.00 price objective on shares of OraSure Technologies and gave the stock a “buy” rating in a report on Thursday, February 9th. Finally, Raymond James Financial, Inc. upgraded shares of OraSure Technologies from a “market perform” rating to an “outperform” rating and set a $11.25 price objective for the company in a report on Thursday, February 9th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $12.04.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.